Abstract
This paper discusses the potential therapeutic effect of α7-nAChR antagonists for NSCLC (non small cell lung cancer) and MPM (malignant pleural mesothelioma). This therapeutic approach is based on the experimental observations that: (a) functional α7-nAChR are expressed in NSCLC and MPM cells, (b) the activation of these receptors by agonists, namely nicotine, induces cell proliferation and inhibits apoptosis, whereas antagonists have a pro-apoptotic effect. Among competitive α7-nAChR antagonists, d-tubocurarine and -cobratoxin (α-CbT), from the snake venom of Naja, emerged as possible drug candidates. However, some aspects of the samples must be particularly taken into account, such as the particular nature of the sample. Thus, when using natural compounds purified from snake venom, it is important to take into account the factors such as whether the venom sample was derived from different animals, purified by different methods, or contained contaminants of the same molecular weight. Finally, biological activity may be different for different batches, which could also have been stored under different conditions (e.g. temperature, dilution, suspension medium etc.). These factors, affecting the experimental results, are also discussed.
Keywords: NSCLC, MPM, d-tubocurarine, cobratoxin, apoptosis, antineoplastic effect, tissue homeostasis, smoking, lung cancer, Bungarotoxin
Current Drug Targets
Title:Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?
Volume: 13 Issue: 5
Author(s): Alfredo Cesario, Patrizia Russo, Candida Nastrucci, Pierluigi Granone
Affiliation:
Keywords: NSCLC, MPM, d-tubocurarine, cobratoxin, apoptosis, antineoplastic effect, tissue homeostasis, smoking, lung cancer, Bungarotoxin
Abstract: This paper discusses the potential therapeutic effect of α7-nAChR antagonists for NSCLC (non small cell lung cancer) and MPM (malignant pleural mesothelioma). This therapeutic approach is based on the experimental observations that: (a) functional α7-nAChR are expressed in NSCLC and MPM cells, (b) the activation of these receptors by agonists, namely nicotine, induces cell proliferation and inhibits apoptosis, whereas antagonists have a pro-apoptotic effect. Among competitive α7-nAChR antagonists, d-tubocurarine and -cobratoxin (α-CbT), from the snake venom of Naja, emerged as possible drug candidates. However, some aspects of the samples must be particularly taken into account, such as the particular nature of the sample. Thus, when using natural compounds purified from snake venom, it is important to take into account the factors such as whether the venom sample was derived from different animals, purified by different methods, or contained contaminants of the same molecular weight. Finally, biological activity may be different for different batches, which could also have been stored under different conditions (e.g. temperature, dilution, suspension medium etc.). These factors, affecting the experimental results, are also discussed.
Export Options
About this article
Cite this article as:
Alfredo Cesario, Patrizia Russo, Candida Nastrucci, Pierluigi Granone , Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment? , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398900
DOI https://dx.doi.org/10.2174/138945012800398900 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Advances in Imaging Gene-Directed Enzyme Prodrug Therapy
Current Pharmaceutical Biotechnology Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Role of Iodine, Selenium and Other Micronutrients in Thyroid Function and Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening Genistein Affects Expression of Cytochrome P450 (CYP450) Genes in Hepatocellular Carcinoma (HEPG2/C3A) Cell Line
Drug Metabolism Letters The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action
Current Drug Targets Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Platelet-Rich Plasma Induces Mixed Osteogenic/Osteoclastogenic Phenotype in Osteosarcoma SaOS-2 Cells: Role of TGF-Beta
Current Pharmaceutical Biotechnology Editorial [Hot topic: The Role of Pemetrexed in Lung Cancer (Guest Editors: Daoyuan Wang and Jianxing He)]
Current Drug Targets MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Protectors of the Mitochondrial Permeability Transition Pore Activated by Iron and Doxorubicin
Current Cancer Drug Targets